Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

SYSTEMIC SCLEROSIS (SCLERODERMA: SSc) is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal organ failure, and death. One of the most important and early modulators of disease activity is thought to be oxidative stress. Evidence suggests that the free radical nitric oxide (NO), a key mediator of oxidative stress, can profoundly influence the early microvasculopathy, and possibly the ensuing fibrogenic response. Animal models and human studies have also identified dietary antioxidants, such as epigallocatechin-3-gallate (EGCG), to function as a protective system against oxidative stress and fibrosis. Hence, targeting EGCG may prove a possible candidate for therapeutic treatment aimed at reducing both oxidant stress and the fibrotic effects associated with SSc.

• Publication year

  2011

• Venue

  Cardiology Research and Practice

• Publication date

  2011-10-31

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1155/2012/521958PMID 22111028PMCID 3206384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.

  2010cited by this paper
• (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.

  2009cited by this paper
• Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.

  2009cited by this paper
• Antioxidants and CVD

  2008cited by this paper
• The nitration of platelet vasodilator stimulated phosphoprotein following exposure to low concentrations of hydrogen peroxide

  2008cited by this paper
• New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma

  2007cited by this paper
• Inhibition of NADPH oxidase subunits translocation by tea catechin EGCG in mast cell.

  2007cited by this paper
• Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection.

  2007cited by this paper
• The myofibroblast: one function, multiple origins.

  2007cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007influential reference
• Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis.

  2007cited by this paper
• Effect of nitric oxide and peroxynitrite on type I collagen synthesis in normal and scleroderma dermal fibroblasts.

  2007cited by this paper
• A polymorphism in the CTGF promoter region associated with systemic sclerosis.

  2007cited by this paper
• Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis.

  2007cited by this paper
• UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents.

  2007cited by this paper
• FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype.

  2007cited by this paper
• Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis.

  2007influential reference
• Effects of epigallocatechin gallate on diethyldithiocarbamate-induced pancreatic fibrosis in rats.

  2007cited by this paper
• Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways.

  2006cited by this paper
• Heme oxygenase-1: a novel drug target for atherosclerotic diseases?

  2006cited by this paper
• The antifibrogenic effect of (−)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells

  2006cited by this paper
• NO Modulates NADPH Oxidase Function Via Heme Oxygenase-1 in Human Endothelial Cells

  2006cited by this paper
• Lipid peroxidation and trace elements in systemic sclerosis

  2006cited by this paper
• Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine.

  2006influential reference
• Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate.

  2006influential reference
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate inhibits ethanol‐induced activation of pancreatic stellate cells

  2006cited by this paper
• Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

  2006cited by this paper
• Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

  2006influential reference
• Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways.

  2006cited by this paper
• Overexpression of nitric oxide synthase by the endothelium attenuates bleomycin‐induced lung fibrosis and impairs MMP‐9/TIMP‐1 balance

  2006cited by this paper
• Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.

  2006cited by this paper
• Mechanisms and consequences of fibrosis in systemic sclerosis

  2006cited by this paper
• Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.

  2006cited by this paper
• Pathogenesis of Raynaud's phenomenon.

  2005cited by this paper
• Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells.

  2005cited by this paper
• Significant Changes of Peripheral Perfusion and Plasma Adrenomedullin Levels in N-Acetylcysteine Long Term Treatment of Patients with Sclerodermic Raynaud's Phenomenon

  2005cited by this paper
• Platelet-derived Growth Factor and Reactive Oxygen Species (ROS) Regulate Ras Protein Levels in Primary Human Fibroblasts via ERK1/2

  2005cited by this paper
• Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease.

  2005cited by this paper
• Gene expression profiling of NRF2-mediated protection against oxidative injury.

  2005cited by this paper
• Mechanisms of Raynaud’s disease

  2005cited by this paper
• Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement.

  2005cited by this paper
• The basics about nitric oxide.

  2005cited by this paper
• Nitric Oxide Regulates Transforming Growth Factor-β Signaling in Endothelial Cells

  2005cited by this paper
• The transcription factor NRF2 protects against pulmonary fibrosis

  2004cited by this paper
• Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90.

  2004cited by this paper
• Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway

  2004influential reference
• TGF‐β signaling and the fibrotic response

  2004cited by this paper
• Targeted Disruption of TGF-β/Smad3 Signaling Modulates Skin Fibrosis in a Mouse Model of Scleroderma

  2004cited by this paper
• Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

  2004cited by this paper
• Systemic sclerosis: current views of its pathogenesis.

  2003influential reference
• Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.

  2003cited by this paper
• Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.

  2003influential reference
• Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features

  2003cited by this paper
• L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.

  2003cited by this paper
• The nitration of proteins in platelets: significance in platelet function.

  2002cited by this paper
• Beauty and the beast. The nitric oxide paradox in systemic sclerosis.

  2002cited by this paper
• Gene Transfection of H25A Mutant Heme Oxygenase-1 Protects Cells against Hydroperoxide-induced Cytotoxicity*

  2002cited by this paper
• The role of protein nitration in the inhibition of platelet activation by peroxynitrite

  2002cited by this paper
• Factors Involved in the Regulation of Type I Collagen Gene Expression: Implication in Fibrosis

  2002cited by this paper
• Distinct involvement of the Jun‐N‐terminal kinase and NF‐κB pathways in the repression of the human COL1A2 gene by TNF‐α

  2002cited by this paper
• The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression.

  2002cited by this paper
• Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.

  2002cited by this paper
• S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

  2002cited by this paper
• Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.

  2002cited by this paper
• Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha.

  2002cited by this paper
• Antifibrotic role of inducible nitric oxide synthase.

  2002cited by this paper
• Nitric oxide and the regulation of gene expression.

  2001cited by this paper
• Antibodies against oxidized low-density lipoproteins in systemic sclerosis.

  2001cited by this paper
• Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets.

  2001cited by this paper
• Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.

  2001cited by this paper
• Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress.

  2001cited by this paper
• Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.

  2001influential reference
• The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

  2001cited by this paper
• Localization of 3-nitrotyrosine to rheumatoid and normal synovium.

  2001cited by this paper
• Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.

  2000influential reference
• Increased nitric oxide production in patients with systemic sclerosis.

  2000cited by this paper
• Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis.

  2000cited by this paper
• A marked increase in plasma nitrated proteins in children with chronic renal failure

  2000cited by this paper
• Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

  2000cited by this paper
• Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1.

  2000cited by this paper
• Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide.

  1999cited by this paper
• Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease.

  1999cited by this paper
• Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.

  1999cited by this paper
• Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.

  1999cited by this paper
• Up-regulation by human recombinant transforming growth factor beta-1 of collagen production in cultured dermal fibroblasts is mediated by the inhibition of nitric oxide signaling.

  1999cited by this paper
• Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin

  1999cited by this paper
• Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans.

  1999cited by this paper
• Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion.

  1999cited by this paper
• Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment.

  1998cited by this paper
• Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis.

  1998cited by this paper
• VASCULAR REVIEW: The aetiology of Raynaud's phenomenon

  1998cited by this paper
• The Aetiology of Raynaud's Phenomenon

  1998cited by this paper
• Vascular endothelial cell regulation of extracellular matrix collagen: role of nitric oxide.

  1998cited by this paper
• Role of Digital Artery Adrenoceptors in Raynaud's Disease

  1997cited by this paper
• Nitric oxide modulates the c-Jun N-terminal kinase/stress-activated protein kinase activity through activating c-Jun N-terminal kinase kinase.

  1997cited by this paper
• Induction of cell proliferation and collagen synthesis in human small intestinal lamina propria fibroblasts by lipopolysaccharide: possible involvement of nitric oxide.

  1997cited by this paper
• Nitric Oxide Inhibition of Transforming Growth Factor-β and Collagen Synthesis in Mesangial Cells

  1997cited by this paper
• Clinical evidence of peroxynitrite formation in chronic renal failure patients with septic shock.

  1997cited by this paper
• Reduced stress defense in heme oxygenase 1-deficient cells.

  1997cited by this paper
• Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols.

  1997cited by this paper

• Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

  2024cites this paper
• Trace Element Deficiency in Systemic Sclerosis—Too Much Effort for Some Traces?

  2024cites this paper
• Optimization of Microgel Formula Combination of Snail Mucus and Catechin to Accelerate Wound Closure

  2024cites this paper
• Single Donor Infusion of S-Nitroso-Human-Serum-Albumin Attenuates Cardiac Isograft Fibrosis and Preserves Myocardial Micro-RNA-126-3p in a Murine Heterotopic Heart Transplant Model

  2022cites this paper
• Red blood cells in type 1 diabetes and multiple sclerosis and technologies to measure their emerging roles

  2022cites this paper
• Regulation of endothelial nitric oxide synthase in cardiac remodeling.

  2022cites this paper
• The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression

  2022cites this paper
• Regulation of Extracellular Matrix Production in Activated Fibroblasts: Roles of Amino Acid Metabolism in Collagen Synthesis

  2021cites this paper
• Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis

  2021influential citation
• Redox distress in organ fibrosis: The role of noncoding RNAs

  2020cites this paper
• The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species

  2020cites this paper
• State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders

  2020cites this paper
• Interleukin-17: Friend or foe in organ fibrosis.

  2019cites this paper
• Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis.

  2019cites this paper
• A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients.

  2019cites this paper
• Scleroderma: An insight into causes, pathogenesis and treatment strategies.

  2019cites this paper
• Stromal extracellular matrix is a microenvironmental cue promoting resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.

  2019cites this paper
• High prevalence of a variety of autoantibodies in a population of hepatitis C virus‐infected individuals

  2018cites this paper
• The clinical effects of l‐arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon

  2018cites this paper
• The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy

  2018cites this paper
• Oxidative/nitrative stress in the pathogenesis of systemic sclerosis: are antioxidants beneficial?

  2018cites this paper
• Oxidative stress in the pathogenesis of systemic scleroderma: An overview

  2018cites this paper
• Oligomeric proanthocyanidins protect myocardium by mitigating left ventricular remodeling in isoproterenol‐induced postmyocardial infarction

  2018cites this paper
• PHAGOCYTIC ACTIVITY OF NEUTRHOPHILS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND LUNG INJURY

  2017cites this paper
• Epigallocatechin gallate attenuates overload‑induced cardiac ECM remodeling via restoring T cell homeostasis.

  2017cites this paper
• Therapeutic potential of NADPH oxidase 1/4 inhibitors

  2017cites this paper
• Pulmonary Hypertension Associated With Scleroderma and Connective Tissue Disease: Potential Molecular and Cellular Targets

  2017cites this paper
• A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face

  2016cites this paper
• Role of redoximiRs in fibrogenesis

  2015cites this paper
• Experimental Treatments of Endometriosis

  2015cites this paper
• Cytokines in the immunopathology of systemic sclerosis

  2015cites this paper
• Oxidative Damage and Antioxidative Therapy in Systemic Sclerosis

  2014influential citation
• Oxidative Stress and Skin Fibrosis

  2014cites this paper
• Salivary antioxidants in patients with systemic sclerosis.

  2014cites this paper
• Correction: Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis

  2013cites this paper
• An update on the pharmacological management of endometriosis

  2013cites this paper
• Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.

  2013cites this paper
• NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents

  2013influential citation
• Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis

  2013cites this paper
• New treatment strategies and emerging drugs in endometriosis

  2012cites this paper
• The Continuing Challenges of Translational Research: Clinician-Scientists' Perspective

  2012cites this paper